LONDON, 28 April 2021: Arix Bioscience plc, (“Arix”, LSE: ARIX), a global venture capital company focused on investing in and building breakthrough biotech companies, notes that its portfolio company Amplyx Pharmaceuticals (“Amplyx”), a privately-held company dedicated to the development of therapies for debilitating and life-threatening diseases that affect people with compromised immune systems, has been acquired by Pfizer Inc.

The acquisition of Amplyx follows an initial equity investment by Pfizer in December 2019 as part of Amplyx’s Series C financing. The terms of the transaction will result in a small increase in Arix’s holding value of Amplyx.

The full announcement can be accessed on Pfizer’s website.